新诊断MGMT启动子甲基化胶质母细胞瘤接受放化疗联合或不联合西仑吉肽治疗相关影像学改变
在424例可评估的MGMT启动子甲基化胶质母细胞瘤患者中,按2017年改良RANO标准评估放化疗联合或不联合西仑吉肽后的影像学进展;初步进展后32%出现治疗相关改变,西仑吉肽组较标准治疗组更常见(24% vs 17%)。
要点
- 初步进展后88/274例(32%)出现治疗相关改变,67例(25%)为进展。
- 西仑吉肽组治疗相关改变发生率高于标准治疗组(24% vs 17%)。
- 治疗相关改变主要发生在放疗后前6个月(3个月后54% vs 6个月后13%)。
核心结论
- 按改良RANO标准,MGMT启动子甲基化胶质母细胞瘤的治疗相关改变发生率较既往研究低。
- 西仑吉肽组的治疗相关改变发生率高于标准治疗组。
- 改良RANO标准推荐的确认扫描并非总能获得,反映当前临床实践。
研究设计与样本
- 纳入至少3次随访MRI的患者,评估标准放化疗联合或不联合整合素抑制剂西仑吉肽后的影像学进展。
- 共424例可评估患者,221例(52%)随机入西仑吉肽组,203例(48%)入对照组。
- 初步进展定义为新发或增大病灶的垂直直径乘积和(SPD)较基线增加≥25%。
- 进展需SPD再次增加≥25%;治疗相关改变需初步进展后病灶稳定或消退。
主要发现
- 随访期间274例(65%)出现初步进展,其中88例(32%)为治疗相关改变,67例(25%)为进展。
- 初步进展后119例(43%)无进一步随访。
- 西仑吉肽组治疗相关改变发生率24% vs 标准治疗组17%(相对风险1.3;95%CI 1.004-1.795;P=0.047)。
- 治疗相关改变主要发生在放疗后前6个月(3个月后54% vs 6个月后13%)。
关键数值与推荐
- 初步进展:新发或增大病灶SPD较基线增加≥25%。
- 进展:需SPD再次增加≥25%。
- 治疗相关改变:初步进展后病灶稳定或消退。
临床怎么用
- 原文未据此给出推荐。
局限性
- 确认扫描并非总能获得,反映当前临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiological progression may originate from progressive disease (PD) or pseudoprogression/treatment-associated changes. We assessed radiological progression in O6-methylguanine-DNA methyltransferase (MGMT) promoter-methylated glioblastoma treated with standard-of-care chemoradiotherapy with or without the integrin inhibitor cilengitide according to the modified response assessment in neuro-oncology (RANO) criteria of 2017. METHODS: Patients with ≥ 3 follow-up MRIs were included. Preliminary PD was defined as a ≥ 25% increase of the sum of products of perpendicular diameters (SPD) of a new or increasing lesion compared to baseline. PD required a second ≥25% increase of the SPD. Treatment-associated changes require stable or regressing disease after preliminary PD. RESULTS: Of the 424 evaluable patients, 221 patients (52%) were randomized into the cilengitide and 203 patients (48%) into the control arm. After chemoradiation with or without cilengitide, preliminary PD occurred in 274 patients (65%) during available follow-up, and 88 of these patients (32%) had treatment-associated changes, whereas 67 patients (25%) had PD. The remaining 119 patients (43%) had no further follow-up after preliminary PD. Treatment-associated changes were more common in the cilengitide arm than in the standard-of-care arm (24% vs. 17%; relative risk, 1.3; 95% CI, 1.004-1.795; P = .047). Treatment-associated changes occurred mainly during the first 6 months after RT (54% after 3 months vs. 13% after 6 months). CONCLUSIONS: With the modified RANO criteria, the rate of treatment-associated changes was low compared to previous studies in MGMT promoter-methylated glioblastoma. This rate was higher after cilengitide compared to standard-of-care treatment. Confirmatory scans, as recommended in the modified RANO criteria, were not always available reflecting current clinical practice.
引用
- Flies CM, Friedrich M, Lohmann P, et al. Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide. Neuro Oncol. 2024. PMID: 38219019. doi:10.1093/neuonc/noad247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。